University of California San Diego, La Jolla, San Diego, CA, 92093, USA.
Northwestern University, Chicago, IL, 60611, USA.
Adv Ther. 2023 Dec;40(12):5579-5590. doi: 10.1007/s12325-023-02680-1. Epub 2023 Oct 6.
Patients with metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) are widely treated with osimertinib, the preferred first-line treatment option. However, disease progression inevitably occurs, driven by EGFR-dependent or EGFR-independent mechanisms of resistance. Platinum-based chemotherapy is the recommended treatment following progression with osimertinib but responses to platinum-based chemotherapy are transient. Salvage therapies, which are used after progression on platinum-based chemotherapy, have poor clinical outcomes in addition to substantial toxicity. In this podcast, we discuss the current treatment landscape and emerging therapeutic options for patients with metastatic EGFR-mutated NSCLC whose disease has progressed following treatment with osimertinib and platinum-based chemotherapy.Podcast audio available for this article.
患有转移性表皮生长因子受体（EGFR）突变型非小细胞肺癌（NSCLC）的患者广泛接受奥希替尼治疗，这是首选的一线治疗选择。然而，由于 EGFR 依赖性或 EGFR 非依赖性耐药机制的存在，疾病进展不可避免。奥希替尼治疗进展后，推荐使用铂类化疗，但铂类化疗的反应是短暂的。在铂类化疗进展后使用的挽救疗法除了具有较大的毒性外，临床结局也较差。在本期播客中，我们讨论了奥希替尼和铂类化疗治疗后疾病进展的转移性 EGFR 突变型 NSCLC 患者的当前治疗现状和新的治疗选择。本文提供播客音频。
